Unicycive Therapeutics, Inc. (UNCY)
NasdaqCM · USD · Healthcare · Biotechnology
$3.58 (+0.00%) as of
Key statistics
- Market cap
- 98.07M
- Forward P/E
- 2.47
- EPS (TTM)
- -1.7200
- Dividend yield
- 0.00%
- 52-week range
- 3.3500 – 8.7400
- Beta
- 1.82
- Profit margin
- 0.00%
- Analyst target
- $28.40
- Volume
- 101.47k
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Mountain View, CA, United States
- Employees
- 21
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.